SYRE

SYRE EBITDA Growth

16.43%TTM

Period ending:

SYRE TTM EBITDA YoY %%
SYRE TTM EBITDA YoY %38.53%-118.95%
2015-12-312026-06-30

Source: Financial Modeling Prep (FMP). Trailing twelve months (TTM). TTM flows use four complete reported quarters. Growth compares with the corresponding period one year earlier.

SYRE ebitda growth history

Year-over-year EBITDA growth rate. The available trailing twelve months (ttm) series contains 43 observations from Dec 31, 2015 to Jun 30, 2026.

Spyre Therapeutics Inc EBITDA Growth — Trailing twelve months (TTM)
Period endingEBITDA Growth
16.4277%
3.6572%
18.0466%
17.6632%
-35.6642%
-36.4067%
-63.4293%
-103.71%
-98.15%
-101.2998%
-54.7852%
-16.7874%
3.6838%
-8.3056%
-28.3059%
-26.1095%
-33.0061%
11.5979%
20.3889%
16.7887%
23.2921%
2.1618%
-0.712%
-8.9098%
-32.4206%
-48.8983%
-76.9227%
-100.9645%
-96.7575%
-86.0446%
-64.6977%
-38.3877%
-30.5451%
-24.6949%
-25.9576%
-30.3336%
-42.3445%
-76.6451%
-93.9604%
-94.0635%
-70.6981%
-27.0108%
-26.3478%

Compare ebitda growth

All SYRE financial metrics · SYRE stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.